A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma

on behalf of ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.

Original languageEnglish
Pages (from-to)1266-1274
Number of pages9
JournalBone Marrow Transplantation
Volume54
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Cyclophosphamide
Hematopoietic Stem Cell Transplantation
Transplantation
T-Lymphocytes
Tissue Donors
Safety
Cell Transplantation
Graft vs Host Disease
Fetal Blood
Survivors
Japan
Survival Rate
Clinical Trials
Databases
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma. / on behalf of ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

In: Bone Marrow Transplantation, Vol. 54, No. 8, 01.08.2019, p. 1266-1274.

Research output: Contribution to journalArticle

@article{1912385563c743d0912ed4e1895387d3,
title = "A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma",
abstract = "Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5{\%} and 17.7{\%}, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3{\%} and 55.8{\%}, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.",
author = "{on behalf of ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation} and Makoto Yoshimitsu and Atae Utsunomiya and Shigeo Fuji and Hiroshi Fujiwara and Takahiro Fukuda and Hiroyasu Ogawa and Yoshifusa Takatsuka and Kenji Ishitsuka and Akira Yokota and Hirokazu Okumura and Kazuyoshi Ishii and Akinori Nishikawa and Tetsuya Eto and Akihito Yonezawa and Kaname Miyashita and Junichi Tsukada and Junji Tanaka and Yoshiko Atsuta and Koji Kato",
year = "2019",
month = "8",
day = "1",
doi = "10.1038/s41409-018-0400-5",
language = "English",
volume = "54",
pages = "1266--1274",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma

AU - on behalf of ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation

AU - Yoshimitsu, Makoto

AU - Utsunomiya, Atae

AU - Fuji, Shigeo

AU - Fujiwara, Hiroshi

AU - Fukuda, Takahiro

AU - Ogawa, Hiroyasu

AU - Takatsuka, Yoshifusa

AU - Ishitsuka, Kenji

AU - Yokota, Akira

AU - Okumura, Hirokazu

AU - Ishii, Kazuyoshi

AU - Nishikawa, Akinori

AU - Eto, Tetsuya

AU - Yonezawa, Akihito

AU - Miyashita, Kaname

AU - Tsukada, Junichi

AU - Tanaka, Junji

AU - Atsuta, Yoshiko

AU - Kato, Koji

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.

AB - Currently, allogeneic hematopoietic stem cell transplantation (allo-HCT) is the only available curative modality for patients with adult T-cell leukemia–lymphoma (ATL). When used in conjunction with posttransplantation cyclophosphamide (PTCY) for graft-versus-host disease prophylaxis, allo-HCT from an HLA haplo-identical donor yields promising outcomes for many diseases other than ATL. However, appropriate comparisons with other donor sources, especially cord blood and conventional HLA haplo-identical donors, are needed to validate the safety and efficacy of this modality. In this study, we retrospectively evaluated the outcome of allo-HCT without PTCY in patients with ATL registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database between 1985 and 2015. During that period, 46 patients received allo-HCT without PTCY and survivors were followed for a median of 2316.5 days (range: 220–3884 days). Although the estimated 1- and 5-year overall survival rates of the entire cohort were 34.5% and 17.7%, respectively, the cumulative 1- and 5-year non-ATL mortality rates of 41.3% and 55.8%, respectively, were high. The results of our study will serve as a platform for discussions of the safety and efficacy of haplo-HCT for future clinical trials in patients with ATL.

UR - http://www.scopus.com/inward/record.url?scp=85058470243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058470243&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0400-5

DO - 10.1038/s41409-018-0400-5

M3 - Article

C2 - 30546068

AN - SCOPUS:85058470243

VL - 54

SP - 1266

EP - 1274

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -